This $50 Biotech Stock Primed for $1.5 BILLION Skyrocket NOW! Up 14%!
Could a biotech stock near $50, with decades of history backing its potential, be on the verge of a massive $1.5 billion market opportunity surge? Exelixis, an oncology specialist, just beat Q1 earnings by 14.02% and is benefiting from investors rotating capital towards profitable healthcare names amid a cooling growth market. Furthermore, its CABOMETYX franchise is booming, management is flush with $1.4 billion in cash, and a significant $750 million share buyback is underway, alongside a pivotal December 2026 PDUFA decision for zanzalintinib. This regulatory decision alone could unlock an estimated $1.5 billion opportunity, positioning Exelixis for significant upside even without its contribution factored into current guidance. Discovering such under-the-radar gems requires deep dives, so make sure to subscribe to our channel for more expert analysis and timely investment insights.
Tags/Hashtags: #exelixis #oncology #investing #cabometyx #zanzalintinib #pdufa #exelixis
Leave a Reply